Latest market price
237.60
-4.88-2.01%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -2.94 | Insider Own | 3.15% | Shs Outstand | 59.20M | Perf Week | 32.83% |
| Market Cap | 14.07B | Forward P/E | 181.71 | EPS next Y | 1.31 | Insider Trans | -7.70% | Shs Float | 56.85M | Perf Month | 45.62% |
| Enterprise Value | 13.83B | PEG | — | EPS next Q | — | Short Float | 7.64% | Perf Quarter | 39.05% | ||
| Income | -170.00M | P/S | 20.35 | EPS this Y | — | Short Ratio | 5.04 | Perf Half Y | 69.45% | ||
| Sales | 691.00M | P/B | 19.62 | EPS next Y | 150.85% | ROA | -17.33% | Short Interest | 4.34M | Perf YTD | 110.43% |
| Book/sh | 12.11 | P/C | 41.74 | EPS next 5Y | 78.99% | ROE | -24.91% | 52W High | 248.79 -4.50% | Perf Year | 208.21% |
| Cash/sh | 5.69 | P/FCF | — | EPS past 3/5Y | — | ROIC | -7.22% | 52W Low | 80.91 193.66% | Perf 3Y | 263.91% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 21.45% 17.64% | Gross Margin | 81.13% | Volatility | 8.07% 5.15% | Perf 5Y | 429.06% |
| Dividend TTM | — | EV/Sales | 20.01 | EPS Y/Y TTM | — | Oper. Margin | -9.17% | ATR (14) | 11.32 | Perf 10Y | 585.12% |
| Dividend Ex-Date | — | Quick Ratio | 4.09 | Sales Y/Y TTM | 47.02% | Profit Margin | -24.60% | RSI (14) | 82.58 | Recom | 2.32 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.57 | EPS Q/Q | 393.75% | SMA20 | 33.85% | Beta | 0.66 | Target Price | 218.70 |
| Payout | 0.00% | Debt/Eq | 0.14 | Sales Q/Q | 57.46% | SMA50 | 37.11% | Rel Volume | 2.16 | Prev Close | 242.48 |
| Employees | 1,094 | LT Debt/Eq | 0.14 | Earnings | Feb 16 | SMA200 | 67.97% | Avg Volume | 946.24K | Price | 237.60 |
| IPO Date | Jun 25, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 587.73% 25.58% | Net Debt/EBITDA | — | Volume | 2,046,411 | Change | -2.01% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | Stifel Nicolaus | Hold | $190 → $225 |
| Oct-29-26 | Reiterated | Mizuho Securities | Outperform | $190 → $225 |
| Oct-29-26 | Reiterated | Truist Securities | Buy | $215 → $255 |
| Oct-29-26 | Reiterated | HC Wainwright & Co. | Buy | $195 → $248 |
| Oct-29-26 | Reiterated | Needham | Buy | $201 → $251 |
| Oct-29-26 | Reiterated | Piper Sandler | Overweight | $195 → $240 |
| Oct-13-26 | Reiterated | Mizuho Securities | Outperform | $185 → $190 |
| Oct-12-26 | Reiterated | BTIG | Buy | $202 → $205 |
| Sep-22-26 | Reiterated | Jefferies | Buy | $155 → $210 |
| Aug-20-26 | Reiterated | BTIG | Buy | $164 → $202 |
Latest News· Times ET
Oct-29-26
08:59AM
04:55AM
Oct-28-26
08:31PM
07:05PM
Glaukos Q3 Earnings Call Highlightsmarketbeat.com
04:05PM
Glaukos Announces Third Quarter 2026 Financial Resultsbusinesswire.com
Oct-24-26
Oct-20-26
Oct-20-2603:53AM
Oct-17-26
Oct-14-26
Oct-13-26
Oct-09-26
Company
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 691 | 507 | 383 | 315 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 130 | 114 | 94 | 76 | — | — | — | — | — | |
| Gross Profit | 560 | 393 | 289 | 239 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 435 | 329 | 263 | 224 | — | — | — | — | — | |
| Research and Development | 187 | 151 | 136 | 139 | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 13 | 5 | — | — | — | — | — | |
| Operating Income | -63 | -87 | -122 | -129 | — | — | — | — | — | |
| Interest Expense | 4 | 5 | 10 | 14 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -106 | -102 | -13 | 9 | — | — | — | — | — | |
| Net Income Before Taxes | -175 | -193 | -146 | -134 | — | — | — | — | — | |
| Income Taxes | -5 | -5 | 1 | 1 | — | — | — | — | — | |
| Consolidated Net Income | -170 | -188 | -146 | -135 | — | — | — | — | — | |
| Net Income From Continuing Operations | -170 | -188 | -146 | -135 | — | — | — | — | — | |
| Net Income | -170 | -188 | -146 | -135 | — | — | — | — | — | |
| EPS (Recurring) | -2.94 | -3.28 | -2.77 | -2.78 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.94 | -3.28 | -2.77 | -2.78 | — | — | — | — | — | |
| EPS (Diluted) | -2.94 | -3.28 | -2.77 | -2.78 | — | — | — | — | — | |
| EBITDA | -124 | -146 | -96 | -82 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 20.29 | 12.69 | 20.75 | 12.11 | — | — | — | — | — | |
| Gross Margin | 81.04 | 77.51 | 75.46 | 75.87 | — | — | — | — | — | |
| Operating Margin | -9.12 | -17.16 | -31.85 | -40.95 | — | — | — | — | — | |
| Net Margin | -24.60 | -37.08 | -38.12 | -42.86 | — | — | — | — | — | |
| Shares Outstanding | 59 | 57 | 53 | 48 | — | — | — | — | — | |
| Market Capitalization | 14,018 | 6,436 | 7,947 | 3,816 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Oct 05 '26 | Sale | 164.45 | 1,527 | 251,120 | 69,291 | Oct 07 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Sep 25 '26 | Sale | 154.28 | 1,615 | 249,159 | 70,818 | Sep 28 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Sep 16 '26 | Sale | 166.92 | 1,457 | 243,204 | 72,433 | Sep 18 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Aug 28 '26 | Sale | 180.67 | 13,744 | 2,483,104 | 73,890 | Sep 01 |
| Kliman Gilbert H | Director | Aug 19 '26 | Option Exercise | 25.77 | 2,500 | 64,425 | 39,906 | Aug 20 |
| Kliman Gilbert H | Director | Aug 19 '26 | Sale | 190.00 | 2,500 | 475,000 | 37,406 | Aug 20 |
| Gilliam Joseph E | PRESIDENT & COO | Aug 11 '26 | Option Exercise | 52.94 | 60,000 | 3,176,400 | 132,588 | Aug 13 |
| Gilliam Joseph E | PRESIDENT & COO | Aug 11 '26 | Sale | 179.74 | 60,000 | 10,784,659 | 72,588 | Aug 13 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Aug 07 '26 | Option Exercise | 33.81 | 20,000 | 676,200 | 63,906 | Aug 11 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Aug 07 '26 | Sale | 180.13 | 20,000 | 3,602,600 | 43,906 | Aug 11 |
| WEN LEANA | Director | Jul 31 '26 | Sale | 167.63 | 525 | 88,006 | 21,092 | Aug 03 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 16 '26 | Option Exercise | 38.68 | 10,000 | 386,800 | 53,906 | Jul 21 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 16 '26 | Sale | 160.00 | 10,000 | 1,600,000 | 43,906 | Jul 21 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 09 '26 | Option Exercise | 38.68 | 10,000 | 386,800 | 53,681 | Jul 13 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 09 '26 | Sale | 155.00 | 10,000 | 1,550,000 | 43,681 | Jul 13 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.